EUCTR2007-005100-41-IT进行中（未招募）不适用
Phase I/II/III Pharmacokinetic and outcome study of Inspiration`s Recombinant Factor IX product, IB1001, in subjects with Hemophilia B - ND
INSPIRATION BIOPHARMACEUTICALS0 个研究点目标入组 75 人开始时间: 2009年7月20日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Patient must be willing to give written Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent, make the required study visits, and follow instructions while enrolled in the study 2. Severe (factor IX activity ≤2 U/dL) hemophilia B subjects on demand therapy with a minimum of 3 bleeding episodes over the preceding 6 months or 6 bleeding episodes over the preceding 12 months; subjects on prophylaxis with a bleeding pattern as above demonstrated prior to starting prophylaxis 3. Immunocompetent (CD4 count >400/mm3) and not receiving immune modulating or chemotherapeutic agents 4. Previously treated patients with a minimum of 150 exposure days to a factor IX preparation 5. Platelet count at least 150,000/mm3 6. Liver function: alanine transaminase [ALT] and aspartate transaminase [AST] ≤2 times the upper limit of the normal range 7. Total bilirubin ≤1.5 times the upper limit of the normal range 8. Renal function: serum creatinine ≤1.25 times the upper limit of the normal range 9. Willingness to participate in the trial for up to 12-15 months 10. European Union (EU), Israel, and Canada: Age of at least 12 years and body weight of ≥40 kilograms to participate in any PK Study or the Surgical Sub-study; age of at least 12 years for the prophylaxis and on demand components of the Treatment Phase and Continuation Study United States (US): Age of at least 12 years and body weight of ≥40 kilograms to participate in any PK Study or the Surgical Sub-study; age of at least 5 years for the prophylaxis and on demand components of the Treatment Phase and Continuation Study 11. Hemoglobin ≥7 g/dL at the time of the blood draw
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of factor IX inhibitor ≥0.6 Bethesda units (BU) 2. Existence of another coagulation disorder 3. Evidence of thrombotic disease, fibrinolysis, or disseminated intravascular coagulation (DIC) 4. Use of an investigational drug within 30 days prior to study entry 5. On medications that could impact hemostasis, such as aspirin 6. History of poor compliance, a serious medical or social condition, or any other circumstance that, in the opinion of the investigator, would interfere with participation or compliance with the study protocol 7. History of adverse reaction to either plasma-derived factor IX or recombinant factor IX that interfered with the subject?s ability to treat bleeding episodes with a factor IX product
研究者
相似试验
进行中（未招募）
1 期
Study of Recombinant Factor IX Product, IB1001, in Subjects with Haemophilia BEUCTR2007-005100-41-GBAptevo Europe Limited80
已完成
3 期
A clinical trial to study the effects of Recombinant Factor IX product IB-1001 in patients with Hemophilia-BCTRI/2011/04/001676Aptevo Bio Therapeutics LLC80
进行中（未招募）
不适用
Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia BMedDRA version: 14.1Level: LLTClassification code 10060614Term: Hemophilia B (Factor IX)System Organ Class: 10010331 - Congenital, familial and genetic disordersHemophilia BEUCTR2007-005100-41-PLInspiration Biopharmaceuticals80
进行中（未招募）
不适用
Phase I/II/III Pharmacokinetic and Outcome Study of Inspiration's Recombinant Factor IX Product, IB1001, in Subjects with Hemophilia BProphylaxis and treatment of bleeding in patients with Hemophilia BMedDRA version: 9.1Level: LLTClassification code 10060614Term: Hemophilia B (Factor IX)EUCTR2007-005100-41-FRInspiration Biopharmaceuticals75
招募中
3 期
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis Subjects 1 Through 11 Years of AgeCystic Fibrosis2024-513754-29-00Vertex Pharmaceuticals Inc.15